Tim Fields, VP Quality, Receives Ken Chapman Industry Recognition Award

MERIDEN, Conn., Oct. 24, 2012 /PRNewswire/ -- Protein Sciences announced that Tim Fields, Vice President of Quality, was named recipient of the Ken Chapman Industry Recognition Award during the International Validation Week Conference presented by the Institute of Validation Technology (IVT) on Oct. 23, 2012. 

Ken Chapman who died of pancreatic cancer in 2006 was renowned for his forward-thinking approach to regulatory issues and best practices. Many of his ideas have become standard in industry.  Tim was recognized for his continued contributions to the pharmaceutical and biopharmaceutical industries in compliance, quality, and validation.

Manon Cox, CEO, commented, "We are extremely proud that Tim is the recipient of this prestigious award. It is an important acknowledgement of his contributions in the field."  She added, "Receiving the Ken Chapman award has special meaning to Tim as they worked together for almost 20 years and he learned to apply his practical approach to compliance and validation."

Tim joined Protein Sciences in 2010 as Director of Compliance and Training, and subsequently served as Senior Director of Quality Operations before becoming VP of Quality in 2011. He has more than 30 years of experience in the pharmaceutical industry, including more than 13 years at Pfizer and 16 years as a GMP compliance consultant. Tim has extensive experience in various areas of compliance, including quality systems, validation, aseptic processing, computerized system validation, GMP training, 21CFR Part 11, document management and auditing. He is a member of PDA and ISPE and is on the editorial review board for the Journal of Validation and Journal of GXP Compliance.

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. 

Our lead product, FluBlok, is a recombinant trivalent vaccine for seasonal influenza, consisting of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using cell culture instead of eggs.  FluBlok is highly purified, does not include thimerosal or antibiotics, and is low in endotoxins.  FluBlok, which has shown exceptional performance in clinical trials, is under final review by the U.S. Food and Drug Administration.

Learn more at www.proteinsciences.com

SOURCE Protein Sciences Corporation

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.